دورية أكاديمية
P207 COVID-19: a prevalence rate two times lower than that of the general population in French patients with Inflammatory Bowel Disease treated with intravenous biologic agents
| العنوان: | P207 COVID-19: a prevalence rate two times lower than that of the general population in French patients with Inflammatory Bowel Disease treated with intravenous biologic agents |
|---|---|
| المؤلفون: | Lelong, M, Nancey, S, Bouguen, G, Allez, M, Serrero, M, Chupin, A, Caillo, L, Viennot, S, Blanc, P, Reimund, J M, Laharie, D, Olivier, R, Laurent, P B, Dib, N, De Maissin, A, Montuclard, C, Trang-Poisson, C, Gaillot, G, Bressollette-Bodin, C, Berthome, M, Burel, M, Vavasseur, F, Bourreille, A, Le Berre, C |
| المصدر: | Journal of Crohn's and Colitis ; volume 16, issue Supplement_1, page i265-i266 ; ISSN 1873-9946 1876-4479 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Gastroenterology, General Medicine |
| الوصف: | Background Patients with Inflammatory Bowel Disease (IBD), either Crohn’s Disease (CD) or Ulcerative Colitis (UC), treated with immunosuppressants and/or biotherapy might have an altered immune response to SARS-CoV-2 infection. The aim of this study was to evaluate the incidence of COVID-19 in a French cohort of IBD patients treated with infliximab or vedolizumab during the first epidemic wave and to identify factors associated with the risk of infection. Methods All patients with IBD treated with infliximab or vedolizumab from March to June 2020 in 16 French centres were included and followed for 6 months. At baseline, clinical, demographic, family and socio-professional data were collected. At each of their day hospitalization, patients reported the occurrence of symptoms of COVID-19, and the performance of a diagnostic test, if so. Serum was collected at each visit to detect immunisation by SARS-CoV-2 at the end of follow-up and to measure trough levels. Peripheral blood lymphocytes (PBLs) were frozen at each visit for 50% of patients to further analyse the immunological changes associated with COVID-19. Results 1079 patients were included (CD n=690, mean age 41.6 years, mean disease duration 13.3 years). Clinical and demographic data at baseline are detailed in Tables 1 and 2, respectively. 143 patients (13.3%) had one or more co-morbidities associated with a risk of severe COVID-19 (hypertension 5.6%, chronic lung disease 5%, diabetes 2.4%, obesity 0.3%). Over the 6 months of follow-up, 458 patients (42%) had active disease defined by an HBI score >4 or Mayo score >2 and/or treatment optimisation (dose increase, shortening of infusion interval, addition of an immunosuppressant or change of biotherapy). 111 patients (10.2%) received corticosteroids at least occasionally (self-medication was not excluded). 341 patients (32%) were tested for COVID-19 by nasal swab, of whom 23 were positive. Three patients were hospitalized. Regarding serology, in the first 13 centres analysed hitherto ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/ecco-jcc/jjab232.334 |
| الإتاحة: | https://doi.org/10.1093/ecco-jcc/jjab232.334Test https://academic.oup.com/ecco-jcc/article-pdf/16/Supplement_1/i265/42251297/jjab232.334.pdfTest |
| حقوق: | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_modelTest |
| رقم الانضمام: | edsbas.22EBFE66 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/ecco-jcc/jjab232.334 |
|---|